Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of NBM-BMX in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma Who Completed Study NBM-BMX-003 (the Parent Study)

NCT07569042 is registered in ClinicalTrials.gov with Novelwise Pharmaceutical Corporation as lead sponsor.

NCT NCT07569042
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07569042 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of NBM-BMX in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma Who Completed Study NBM-BMX-003 (the Parent Study)
Lead sponsor
Novelwise Pharmaceutical Corporation
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 20, 2026
Completion date
December 31, 2030
Enrollment
15 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

malignant neoplasm of brain